参考文献
[1] Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2013,62(16):e147-239. DOI: 10.1016/j.jacc.2013.05.019.
[2] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur J Heart Fail, 2016,18(8):891-975. DOI: 10.1002/ejhf.592.
[3] Butler J, Anker SD, Packer M. Redefining heart failure with a reduced ejection fraction[J]. JAMA, 2019[Epub ahead of print].DOI: 10.1001/jama.2019.15600.
[4] Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging[J]. Eur Heart J Cardiovasc Imaging, 2015,16(3):233-270. DOI: 10.1093/ehjci/jev014.
[5] Moliner P, Lupón J, Barallat J, et al. Bio-profiling and bio- prognostication of chronic heart failure with mid-range ejection fraction[J]. Int J Cardiol, 2018,257:188-192. DOI: 10.1016/j. ijcard.2018.01.119.
[6] Lund LH, Claggett B, Liu J, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum[J]. Eur J Heart Fail, 2018,20(8):1230-1239. DOI: 10.1002/ejhf.1149.
[7] Solomon SD, Claggett B, Lewis EF, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction[J]. Eur Heart J, 2016,37(5):455-462. DOI: 10.1093/eurheartj/ehv464.
[8] Solomon SD, McMurray J, Anand IS, et al. Angiotensin-neprilysin inhibition in heart Failure with preserved ejection fraction[J]. N Engl J Med, 2019,381(17):1609-1620. DOI:10.1056/NEJMoa1908655.
[9] Cleland J, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials[J]. Eur Heart J, 2018,39(1):26-35. DOI: 10.1093/eurheartj/ehx564.
[10] Tsao C W, Lyass A, Enserro D, et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction[J]. JACC Heart Fail, 2018,6(8):678-685. DOI: 10.1016/j.jchf.2018.03.006.